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Synthetic biology is an emerging ﬁeld focusing on engineering genetic devices and biomolecular systems
for a variety of applications from basic biology to biotechnology and medicine. Thanks to the tremendous
advances in genomics and the chemical synthesis of DNA in the past decade, scientists are now able to
engineer genetic devices and circuits for cancer research and intervention, which offer promising
therapeutic strategies for cancer treatment. In this article, we provide a systemic review on recent
development achieved by the synthetic biologists, oncologists and clinicians of one National “973” Plan.
We expand the synthetic biology toolkits involving DNA, RNA and protein bio-parts to explore various
issues in cancer research, such as elucidation of mechanisms and pathways, creation of new diagnostic
tools and invention of novel therapeutic approaches. We claimed that the Chinese synthetic biologists
are promoting the basic research productions of tumor synthetic biology into the clinic.
© 2016 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Urinary bladder cancer (BCa) is the most common urinary tract
malignancy with high recurrence and mortality rates all around theReprogramming Technology,
d Hospital of Shenzhen Uni-
le's Republic of China.
), caizhiming2000@163.com
nications Co., Ltd.
er B.V. on behalf of KeAi Communworld. Each year, bladder cancer is diagnosed in about 80500 pa-
tients in the China and in more than 429793 patients worldwide,
making it the 5th most common cancer in men and the 9th most
common cancer in both sex [1,2]. Although the cancer therapy has
achieved some improvements, the trends in BCa incidence and
mortality has not been decreased signiﬁcantly in recent years which
indicate that the developments of therapies for BCa were not ideal.
What's more, limited speciﬁcity and efﬁciency were shown in cur-
rent therapies for BCa, such as chemotherapy, surgery and radiation
[3e5]. An innovative and precise treatment is crucially required in
this issue and further studies will be needed to pinpoint the concrete
pathogenesis of BCa. Since the unparalleled progresses in cancerications Co. This is an open access article under the CC BY-NC-ND license (http://
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captured our great attention. The application of systems biology and
panomic analysis to analyze the cause of an individual patient's
disease plays a vital role in precision medicine. A comprehensive
analysis of genetic alterations in BCa was performed in our former
studies which show frequent mutations of chromatin remodeling
genes and frequent alterations in genes involved in sister chromatid
cohesion and segregation [6,7]. Moreover, we screened somatic
mutations of BCa and found that mutation of the androgen receptor
gene is not associated with BCa and mutant TERT promoter may
serve as potential markers for the differential diagnosis and sur-
veillance of BCa [8,9]. Together, these data reveal the necessity of
epigenomics research in the future cancer studies.
As mentioned above, current situation calls for the need to
develop a novel powerful therapy which could fulﬁll precision
medicine. Although still in its infancy, synthetic biology approach
has been used in biomedical ﬁeld. Synthetic medicine is an
emerging scientiﬁc ﬁeld at the interface of synthetic biology and
medicine that creates functional devices for clinical medical uses.
The main goal of medical synthetic biology is to develop technol-
ogies that are designed to assist in diagnosis or reverse disease
states. They are believed to reach the clinical setting in the near
future. Just in recently, an increasing number of original functional
circuits are designed and created to expand the tools available for
therapeutic and research applications. From bacterial hosts to
mammalian cells, synthetic biologists have opened a door for
updating our knowledge of cellular networks and stimulating the
development of novel therapeutic approaches, especially in cancers
[10,11]. Severe side effect and large scale damage of noncancerous
cells were usually happened in conventional therapies, such as
chemotherapy and radiation [12]. Beneﬁted from the versatile
cancer-killing switches and engineered cells, precision and efﬁcacy
in targeting and killing cancer cell have been greatly improved.
Moreover, the cancer cellular behavior can be rewired to produce
new behaviors [13]. All of these studies have enabled more and
more novel strategies to treat cancers.
During recent years, tumor synthetic biologyhas alreadycaptured
a huge attention fromChina's government and a series of investment
on this topic has signiﬁcantly increased in the coming years. Project
“Bladder Cancer Intervention with Engineered Bio-devices project”,
one of theNational Key Basic Research Plan (theNational “973” Plan),
has been launched to keep Chinese synthetic biologists in the fore-
front of this emerging ﬁeld for the transformation of tumor synthetic
biology into the clinic. In this review, we focus the recent develop-
ment on synthetic biological devices treating bladder cancer in the
National “973” Plan. Throughout, we discuss the progress and per-
spectives of tumor synthetic biology in China.
2. The progress of tumor synthetic biology in “973” Plan
2.1. BCa targets identiﬁed by genetic switches
Although various useful prediction models of BCa have been
reported in recent years, there is still a requirement for more novel
biomarkers for improving the speciﬁcity and reliability of predic-
tion tools for BCa [4]. Accumulating pioneering studies suggested
that lncRNAs are involved in development in different cancers [14].
Further comprehensive mechanism between lncRNA and BCa was
discovered in continuance [15]. Thus, the identiﬁcation of BCa-
associated lncRNAs may provide an opportunity to better under-
stand the mechanism network of cancer pathogenesis in BCa for
future targeted treatment. In contrast to the traditional researches,
we applied a novel strategy to identify the functional BCa-
associated lncRNAs. Based on the engineering principle of syn-
thetic biology, we constructed tetracycline-inducible RNAi devicestargeting BCa-associated genes. Beneﬁted from the tet-RNAi device,
we can regulate the expression of the target genes in doxycycline
dosage-dependent manner for the veriﬁcation of its function in
BCa. In order to prove the utility of these devices, we have con-
structed artiﬁcial miRNAs that target lncRNAs or protein-coding
mRNAs. These devices could induce anti-cancer effects by
silencing targeted protein-coding genes or non-coding genes,
accordingly [16]. Then tet-shRNA/miRNA were constructed to
target and silence star-oncogene.We found that both the tet-shRNA
[17] and tet-miRNA [18] could effectively silence the target genes
and inhibit related malignant phenotypes of BCa, such as induction
of BCa cell apoptosis, inhibition of BCa cell proliferation and sup-
pression migration. To further expand on this issue, we evaluated
the function of BCa-related lncRNAs by the tet-RNAi devices after
series of preliminary function tests [19,20]. The lncRNA-associated
malignant phenotypes of BCa can be quantitatively regulated by
controlling the relative expression of target lncRNAs. To improve
the RNAi efﬁciency in target regulation, we construct the
tetracycline-inducible double shRNAs targeting multi-lncRNAs
[21]. Together, lncRNA PVT1, HIF1A-AS2 and CCAT2 might serve
as oncogenes in BCa and might be employed as potential thera-
peutic targets for BCa by the further identiﬁcation of the tet-RNAi
device. Through the useful tet-RNAi devices, the target genes
could be precisely regulated in a dosage-dependent manner. So we
can accurately identify novel and useful biomarkers for precision
cancer treatment.
2.2. Cancer speciﬁc promoter for driving anti-target devices
Tumor speciﬁc promoters are speciﬁcally activated in tumor
cells, such as AFP promoter in hepatocellular carcinoma, PSA pro-
moter in prostate cancers and so on. All these promoters have
presented an novel and effective approach to improve the speci-
ﬁcity of cancer therapy. In the previous work [8], we found that the
somaticmutations in TERT promoter can be detected in 55.6% of the
BCa, and that these mutations can up-regulate the expression of
hTERT and enhanced related tumor-speciﬁc feature in BCa. Also the
mutant hTERT promoter has a higher transcriptional activity in BCa
and affects patient survival and disease recurrence [22]. Hence,
mutant hTERT promoter can be employed as useful BCa-speciﬁc
element in anti-BCa module. Based on these studies, we con-
structed synthetic miRNA sponges (Fig. 1A) which could selectively
suppress the expression of oncogenic miRNAs driven by mutant
hTERT promoter [23]. This miRNA sponges not only inhibited pro-
liferation and migration but also induced apoptosis by suppression
of miR-17-5p, miR-20a, miR-96, and miR-183 in BCa cell while
human ﬁber cells were nearly not affected by the miRNA sponge. It
was manifested that the synthetic miRNA sponges driven by
mutant hTERT promoter had tumor-speciﬁc effects on BCa cells.
Based on the wild-type hTERT promoter sequence, we constructed
the artiﬁcial hTERT promoter that has a signiﬁcantly improved
driven efﬁciency and still retains a high cancer-speciﬁcity in BCa.
The driven efﬁciency of artiﬁcial hTERT promoter was associated
with ETS-1. Furthermore, the Bax-Anti Bcl2 combination module
(Fig. 1B) driven by artiﬁcial hTERT promoter could speciﬁcally and
effectively inhibit malignant phenotypes of BCa by reversing the
ratio of Bcl2/Bax [24]. Both mutant hTERT promoter and artiﬁcial
hTERT promoter could robustly and speciﬁcally induce the
expression of synthetic modules, thus presenting a notable strategy
for tumor-targeting therapies.
2.3. Logical and gates for identiﬁcation of bladder cancer
The CRISPR (clustered regularly interspersed with short palin-
dromic repeat)/Cas is derived from the immune systems of bacteria
Fig. 1. Design and construction of anti-target devices driven by cancer speciﬁc promoter. A. The schematic representations of the synthetic miRNA sponges driven by mutant hTERT
promoter. The suppression of oncogenic miRNAs was only detected in BCa cells while normal cells were nearly not affected. B. The schematic representations of the artiﬁcial hTERT
promoter-Bax-Anti Bcl2 combination module. In the BCa cell, the expression level of transcription factor ETS-1 is high and thus the artiﬁcial promoter is active. Oppositely, ETS-1 is
absent and the artiﬁcial promoter is inactive in the normal cells.
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modiﬁcation of the target site sequence. Until recently, scientists
have begun to use this system to generate targetedmutations in the
genomes of animals. To date, researchers have successfully applied
the CRISPR/Cas system to human, mouse, zebraﬁsh, silkworm,
Drosophila, yeast, Arabidopsis thaliana and rice. It is also used to
explore the mechanisms of a series of human diseases such as
cancer, AIDS, and inherited disorders [25]. We reported an article in
Nature Communications, in which our group constructed an AND
gate genetic circuit (Fig. 2A) based on the CRISPR-Cas9 system [26].
The genetic circuit integrates the information from the two pro-
moters as the input, and the output signal is activated only when
the two inputs are activated in the test cell lines (Fig. 2B). Using
luciferase reporter gene as a genetic output (Fig. 2C), we conﬁrmed
that compared to human telomerase reverse transcriptase (hTERT)
- Renilla ﬂuorescence enzyme (Renilla luciferase) constructs, this
circuit can speciﬁcally detect bladder cancer cells and signiﬁcantly
improve the luciferase expression. In addition, hbax, p21 and E-
cadherin were used to replace the luciferase reporter gene as the
output gene (Fig. 2C), and the results showed that the malignant
phenotypes of bladder cancer cells can be inhibited effectively by
regulating the corresponding genes. This method provides a syn-
thetic biological platform for the in vitro targeting and control of
bladder cancer cells.2.4. Redirecting oncogenic signaling to an antioncogenic pathway
We also reconstructed the CRISPR-Cas9 system by combining
the riboswitch recognizing speciﬁc biological signal into the sgRNA
scaffold [27] (Fig. 3). These newly-engineered genetically-encodeddevices carry and distribute external or internal input signal cur-
rents to produce designated output responses, thus functioning as
“signal-conductors” that build interconnection networks for signal
redirecting applications. In themolecular design of one such device,
the riboswitch responds to one speciﬁc small molecule or protein
signal while the binding motif of sgRNA targets the gene encoding
another signal and interferes with transcription, either positively or
negatively. A different transcriptional responsewill result in a novel
cell fate decision. This work supports the idea that cellular signals
can be connected in novel combinations by the CRISPReCas9-based
signal-conductors, which suggests a new dimension to the ability of
CRISPRs to edit complex cellular processes. We used these signal-
conductors to build a set of transcriptional logic gates which inte-
grate endogenous signals as the inputs and control the expression
of one cellular gene as the output. We also show that the signal-
conductors can be used to establish synthetic cross-talks between
different signaling pathways in bladder cancer cells. Furthermore,
we demonstrate that these devices can act as a master redirector of
oncogenic signals and thus reprogram the fate of bladder cancer
cells. By rewiring gene networks we can shed light on the treat-
ment of bladder cancer that occurs when native networks are
damaged. These new devices may facilitate a new approach to
selectively kill cancer cells in which the oncogenic signals are
dysregulated, because they can link the oncogenic signals to the
activation of anti-oncogenic signals.3. Perspective and future works
The above proposed synthetic biology strategy will provide a
novel therapeutic approach with high speciﬁcity and efﬁciency
Fig. 2. Design and construction of the AND gate genetic circuits. A. The designed circuit is based on the CRISPR/Cas9 system and used the hTERT and hUP II promoters as the two
inputs. B. General principle of the AND gate circuit in identiﬁcation of bladder cancer cells. The circuit only produces a high output in bladder cancer cells. C. The schematic
representations of the synthetic circuits. The output genes were hRluc, hBAX, p21 and E-cadherin, respectively.
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bladder cancer treatments. Developing artiﬁcial biological systems
to control the malignant phenotypes of tumor cells also can answerFig. 3. General illustration of the CRISPReCas9-based signal-conductor. The device was co
which was exposed due to a conformational change after the signal bound to the aptamer. I
expression.many fundamental scientiﬁc problems, and greatly promote the
development in the ﬁeld of cancer therapy. In the future works, we
will test the efﬁciency and speciﬁcity of these synthetic devices inmposed of two parts: a sensing module, made of a riboswitch; and a sgRNA module,
t allowed highly responsive, dose-dependent and dynamic control of mammalian gene
Z. Chen et al. / Synthetic and Systems Biotechnology 1 (2016) 216e220220the treatment of mice and patients suffering from bladder cancer,
further optimize speciﬁc killing effects on bladder cancer and
extend this approach to other types of tumors. Even though syn-
thetic circuit therapy is making its way to treat a number of human
cancers since the recent years of basic experimental research, the
safe and effective use of gene delivery system remains a challenge.
The future works should also improve the gene delivery vectors
(e.g. the nanoparticles) and use the principles of controlled release
strategies to increase the biosafety.
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